PMID- 33663076
OWN - NLM
STAT- MEDLINE
DCOM- 20210316
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 8
DP  - 2021 Feb 26
TI  - The effect of pretreatment BMI on the prognosis and serum immune cells in 
      advanced LSCC patients who received ICI therapy.
PG  - e24664
LID - 10.1097/MD.0000000000024664 [doi]
LID - e24664
AB  - This study aims to evaluate the prognosis and serum immune cells of patients with 
      different pretreatment body mass index (BMI) values. The data of 61 newly 
      diagnosed patients with advanced lung squamous cell carcinoma (LSCC) who received 
      immune checkpoint inhibitors (ICIs) combined with chemotherapy were obtained from 
      the database of Rizhao People's Hospital (Rizhao, Shandong). According to the 
      cutoff value of BMI (23.2 kg/m2), 32 patients had a high BMI and the remaining 29 
      patients had a low BMI. The effects of different BMIs on the prognosis and serum 
      immune cells of patients were analyzed. The median progression-free survival 
      (PFS) times were 7.72 months in the high BMI group and 4.83 months in the low BMI 
      group [adjusted hazard ratio (HR), 0.23; 95% confidence interval (CI), 0.11-0.48; 
      P < .001]. In terms of the overall survival (OS), the median times of the high 
      BMI group and low BMI group were 18.10 and 13.90 months, respectively (adjusted 
      HR, 0.15; 95% CI, 0.07-0.32; P < .001). After 4 cycles of ICI therapy combined 
      with chemotherapy, the objective response rate was 59.4% for the high BMI group 
      and 20.7% for the low BMI group (P = .002). In addition, the number of serum 
      immune cells in patients with high BMI was significantly higher than that in 
      patients with low BMI (all P < .001). There was a linear relationship between BMI 
      value and the number of serum immune cells (all R2 > 0.7). The current results 
      showed that high BMI is associated with better prognosis in LSCC patients who 
      received ICIs, which may be related to higher levels of serum immune cells.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Oncology, The Rizhao People's Hospital, Rizhao, Shandong, PR China.
FAU - Zhou, Lei
AU  - Zhou L
FAU - Chen, Na
AU  - Chen N
FAU - Li, Xiaoming
AU  - Li X
AUID- ORCID: 0000-0001-8262-4105
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Body Mass Index
MH  - CD4 Lymphocyte Count
MH  - CD4-CD8 Ratio
MH  - CD8-Positive T-Lymphocytes
MH  - Carcinoma, Squamous Cell/*drug therapy/mortality/pathology
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*therapeutic use
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Sex Factors
MH  - Survival Analysis
PMC - PMC7909129
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2021/03/06 06:00
MHDA- 2021/03/17 06:00
PMCR- 2021/02/26
CRDT- 2021/03/05 01:00
PHST- 2020/08/12 00:00 [received]
PHST- 2021/01/19 00:00 [accepted]
PHST- 2021/03/05 01:00 [entrez]
PHST- 2021/03/06 06:00 [pubmed]
PHST- 2021/03/17 06:00 [medline]
PHST- 2021/02/26 00:00 [pmc-release]
AID - 00005792-202102260-00039 [pii]
AID - MD-D-20-07766 [pii]
AID - 10.1097/MD.0000000000024664 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Feb 26;100(8):e24664. doi: 
      10.1097/MD.0000000000024664.